



Melinta Therapeutics

The Antibiotics Company

Jefferies Conference

President and CEO

Dan Wechsler

June 6, 2018

Cautionary Note Regarding Forward-looking Statements

- This presentation contains forward-looking statements that involve a number of risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
- You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. We are under no obligation (and expressly disclaim any such obligation) to update or revise any forward-looking statement that may be made from time to time, whether as a result of new information, future developments or otherwise.
- Risks and uncertainties for Melinta Therapeutics, Inc. (the “Company”) are more fully described in the Company’s filings with the SEC, including in its most recently filed Annual Report on Form 10-K, its most recently filed Quarterly Report on Form 10-Q and its Current Reports on Form 8-K.

Who is Melinta Therapeutics?

- Antibiotics-focused company, recently listed on Nasdaq (MLNT)
- Four US FDA approved antibiotics
- Fully-established & highly leverageable operating infrastructure
- Well-experienced, ID-focused leadership team
- Deep, sustainable pipeline of early- to late-stage assets
- Strong market exclusivity period afforded by GAIN Act and IP
- *Well capitalized to support strong future growth*

Leading Pure-play Antibiotics Company

A New Model for Success in Antibiotics

Company	Multiple Approved Products	Gram-negative Pipeline	Successful Phase 3 Program	Multiple Late-stage Indications	Sustainable Discovery Capabilities
Melinta (MLNT)	✓	✓	✓	✓	✓
Achaogen (AKAO)		✓	✓		
Paratek (PRTK)	✓		✓		
Tetraphase (TTPH)	✓	✓			✓
Nabriva (NBRV)	✓				

Source: Company estimates

Robust and Complementary Product Portfolio of Four Approved Assets with Significant Commercial Potential



ABSSSI Patients with Comorbidities in the Hospital, Emergency and Outpatient Setting



Orbactiv®
(oritavancin)
for injection

Gram (+) ABSSSI in the Emergency and Outpatient Setting

Minocin®
(minocycline)
for injection



Acinetobacter in the Hospital Setting

Unique Market Value for Each Approved Product Optimized By Company Infrastructure and Commitment to Antibiotics

Industry Leading Portfolio and Pipeline

PRODUCT/INDICATION	PRE CLINICAL	PHASE 1	PHASE 2	PHASE 3	NDA Submitted	FDA Approved	EMA Submitted	EMA Approved
Baxdela Acute Bacterial Skin and Skin Structure Infections (ABSSSI)	[Progress bar: Pre-clinical, Phase 1, Phase 2, Phase 3, NDA Submitted, FDA Approved, EMA Submitted]							
Vabomere Complicated Urinary Tract Infections (cUTI)	[Progress bar: Pre-clinical, Phase 1, Phase 2, Phase 3, NDA Submitted, FDA Approved, EMA Submitted]							
Orbactiv ABSSSI	[Progress bar: Pre-clinical, Phase 1, Phase 2, Phase 3, NDA Submitted, FDA Approved, EMA Submitted]							
Minocin IV Serious infections due to select organisms including <i>Acinetobacter</i>	[Progress bar: Pre-clinical, Phase 1, Phase 2, Phase 3, NDA Submitted, FDA Approved]							
Baxdela Community-acquired Bacterial Pneumonia (CABP)	[Progress bar: Pre-clinical, Phase 1, Phase 2]							
Radezolid Dermatology	[Progress bar: Pre-clinical]							
ESKAPE "Superbugs"	[Progress bar: Pre-clinical]							
Other Non-Core Assets	[Progress bar: Pre-clinical, Phase 1, Phase 2, Phase 3, NDA Submitted, FDA Approved, EMA Submitted]							
Fusidic Acid ABSSSI	[Progress bar: Pre-clinical, Phase 1, Phase 2]							
	One positive phase III complete.							
Solithromycin CABP	[Progress bar: Pre-clinical, Phase 1, Phase 2, Phase 3, NDA Submitted, FDA Approved]							
	Development ongoing in Japan through partner. Potential for other indications.							

Successful Out-licensing Offers Potential to Expand Partnerships Across Full Portfolio of Assets



Active process underway to license global rights to products acquired from The Medicines Company

Melinta's 2018 Corporate Objectives

1. Maximizing Product Portfolio

2. Financial & Operational Strength

3. Advancing New Drug Portfolio

Q1 and YTD Business Highlights

Maximizing Product Portfolio

- \$14.8 million of net revenue* in Q1
 - \$11.8 million of net product sales in Q1
- Launched Melinta Antimicrobial Stewardship Program at MAD-ID
- Strong presence at all major ID- related medical meetings with ~20 posters at upcoming ASM-Microbe meeting

Financial & Operational Strength

- Integration of The Medicines Company ID Business complete
 - Sales force cross training complete – new incentive plan in place
 - Cost synergies to be achieved
 - Sales force expanded to maximize company portfolio of products
- Actively evaluating BD opportunities to monetize valued portfolio ex-US

Advancing New Drug Portfolio

- Baxdela CABP trial enrollment on target
- Vabomere EU application on target
- CARB-X funding received to support advancement of new antibiotic class
- Strong ECCMID presence with 12 posters & presentations
- Submissions of delafloxacin ongoing in Europe and Latin America


Fully capitalized with recent offering to support current growth plans of the company

Vabomere™: Launch Momentum Continues



- 97 formulary approvals to-date
- 99% Formulary Approval
- ~200 unique accounts ordering
- 52% of accounts reordering

Cumulative Ordering Accounts




Cumulative Ordering Accounts Doubled in Last 13 Weeks

Baxdela™: Off to a Terrific Start




- 177 million patient lives have access
- 90 formulary approvals to-date
- 12 different specialties prescribing
- >30 additional formulary meetings scheduled

Cumulative Health Care Professionals (HCPs) Prescribing



Cumulative Hospital Accounts Ordering



Week-over-week Prescribing Nearly Doubled Over Last 8 Weeks

Orbactiv®: Accelerating Growth Quarter-on-quarter

Orbactiv®
(oritavancin)
for injection


- Average of 48 new accounts per month*
- 70% of volume purchased by the hospital
- >50% demand over Q1 2017

of Accounts Ordering



>30% Quarter-on-quarter Growth

of New Accounts Ordering 5 or More Boxes/Quarter



~40% Quarter-on-quarter Growth


*Over last 6 months

Minocin® IV: Sales Reinvigorated with Vabomere

Minocin®
(minocycline)
for injection

- Double-digit growth vs. Q1 2017 on a pro forma basis
- Increased level of product growth YTD correlation with launch of Vabomere

Boxes Sold By Quarter



*Consistent Quarter-over-quarter Gains;
Early Synergies Reported Alongside Vabomere*

Commercial Efficiency and Optimization Underway

Expands Share of Voice for All Products by 2-3x to ~170 Current

Step 1: Launch



Incentive Plan 1



Incentive Plan 2



Orbactiv® (oritavancin) for injection
Minocin® (minocycline) for injection



Step 2: Optimize



New Incentive Plan



Orbactiv® (oritavancin) for injection



Minocin® (minocycline) for injection



Melinta is Now Powered by CARB-X



- Agreement supporting development of new antibiotic class (the pyrrolocytosine class for ESKAPE pathogens)
- Melinta will receive initial grant of up to \$2.3 million with potential to receive additional \$3.9 million to support existing discovery efforts
- Initial goal of selecting lead candidate & completing IND-enabling program

Strategy for Long-term Growth and Expansion

DRIVE

Sales of >\$1 billion from four US-approved antibiotics

DEVELOP

Additional indications during 10+ years of market exclusivity for key assets afforded by GAIN Act

DISCOVER

Completely novel anti-infectives leveraging our proprietary, Nobel Prize-winning discovery platform

EXPAND

Ex-US partnerships across entire product portfolio to enhance company value

Continue to Execute Growth-accelerating Business Development Activities

2018 Key Catalysts

Maximizing Product Portfolio

- Launch updates for Baxdela and Vabomere
- Country filings/approvals in South & Central America for delafloxacin
- Ex-US partnerships for balance of portfolio
- Baxdela Phase 3 CABP study enrollment completion

Financial & Operational Strength

- Potential cost synergies and lower operating expenses
- Roll out of Melinta Antimicrobial Stewardship Program
- Business development opportunities

Advancing New Drug Portfolio

- EMA regulatory approval for Vabomere
- TANGO-2 additional data and potential publications
- Progress on ESKAPE program
- Focused publication strategy; 30+ planned


When Strategy is Clear, EXECUTION Becomes the Strategy

Q1 2018 Financial Highlights – Strong Start to 2018

Metrics (in millions)	GAAP	Adjustment	Non-GAAP	Comments
Total Net Revenue	\$14.8		\$14.8	Excludes BARDA grant funding
- Product	11.8		11.8	
- Contract	3.0		3.0	
COGS	7.7	(4.7)	3.0	Deal-related amortization
Total Operating Expenses	\$50.8	(4.6)	\$46.1	
- R&D	16.1	(0.3)	15.8	Stock comp
- SG&A	34.6	(4.3)	30.3	Stock comp, M&A-related
Cash & Cash Equivalents	\$91.5		\$91.5	Approximately ~\$165 post financing
Long-term Debt	\$147.8		\$147.8	
Common Shares Outstanding	31.4		31.4	Post financing: 56.0
Options, RSUs and Warrants Outstanding	6.1		6.1	Current: 7.6

Anticipate Orbactiv and Minocin to Achieve Net Sales of \$36-40 Million for FY 2018

Melinta Therapeutics, The Antibiotics Company




Fully Capitalized to Support Strong Future Growth



APPENDIX

Creating the Pure Play Antibiotics Leader



Transformed into Largest Pure-play Antibiotics Company

Vabomere: Fixed Dose, IV Monotherapy Targeting KPC-producing, Carbapenem-resistant Enterobacteriaceae

Indications:

- cUTI (approved)
- Acute pyelonephritis (approved)

Attributes / Differentiation:

- Product for serious Gram-negative pathogens, an area of significant need
- Fixed dose, no requirement for plasma monitoring
- Meropenem “backbone” with safety profile similar to meropenem alone
- Conducted first & only supportive study as monotherapy in CRE infections versus a range of “best available therapy” regimens



- \$990/day WAC
- 2g meropenem / 2g vaborbactam
- TID dosing
- Fixed dose

Baxdela: Fixed Dose, IV/Oral Monotherapy Targeting Serious Mixed Pathogen Infections

Indications:

- ABSSSI (approved)
- CABP (single Phase 3, >75% enrolled)

Attributes / Differentiation:

- Gram-positive, Gram-negative, MRSA (only approved FQ with coverage)
- Interchangeable IV and Oral administration
- Fixed dose, no food effect, no drug interactions (other than antacids)
- <1% discontinuation due to treatment-related AEs in ABSSSI Phase 3s
- Large database of co-morbid patients studied



- \$135/day WAC
- 450mg tablet
- BID dosing
- Fixed dose



- \$265/day WAC
- 300mg vial
- BID dosing
- Fixed dose

Orbactiv & Minocin Strategy

Demonstrating Consistent Growth Since Launch

Orbactiv[®]
(oritavancin)
for injection

Minocin[®]
(minocycline)
for injection

1

Drive Value from Reinvigorated Salesforce

2

Leverage Power of 100% Dedicated
Anti-infectives Business

3

Focus on Newly Accessible Opportunities,
e.g. Outpatient Clinics Surrounding Hospitals

\$34 Million FY 2017 Sales

Attractive Product Portfolio for Multiple Sites of Care

Hospital Avoidance



Baxdela™
(delafloxacin) 450 mg tablets
300 mg vial for injection

Orbactiv®
(oritavancin)
for injection

Hospital



Baxdela™
(delafloxacin) 450 mg tablets
300 mg vial for injection

Orbactiv®
(oritavancin)
for injection

VABOMERE™
meropenem and vaborbactam
for injection (4 g)

Minocin®
(minocycline)
for injection


**Transition of Care
(Post-Discharge)**



Baxdela™
(delafloxacin) 450 mg tablets
300 mg vial for injection

Orbactiv®
(oritavancin)
for injection

**Specialty
Community**



Baxdela™
(delafloxacin) 450 mg tablets
300 mg vial for injection

Orbactiv®
(oritavancin)
for injection